619 related articles for article (PubMed ID: 18351211)
1. Gene therapy for hemophilia "A" and "B": efficacy, safety and immune consequences.
Chuah M; Vandendriessche T
Verh K Acad Geneeskd Belg; 2007; 69(5-6):315-34. PubMed ID: 18351211
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for haemophilia "A" and "B": efficacy, safety and immune consequences.
Chuah MK; Vandendriessche T
Bull Mem Acad R Med Belg; 2007; 162(5-6):357-61. PubMed ID: 18405006
[TBL] [Abstract][Full Text] [Related]
3. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for hemophilia.
Chuah MK; Collen D; VandenDriessche T
J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
[TBL] [Abstract][Full Text] [Related]
5. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
Couto LB
Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for hemophilia.
Ponder KP
Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
8. AAV vectors for hemophilia B gene therapy.
Chao H; Walsh CE
Mt Sinai J Med; 2004 Oct; 71(5):305-13. PubMed ID: 15543431
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for hemophilia: clinical trials and technical tribulations.
Viiala NO; Larsen SR; Rasko JE
Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
[TBL] [Abstract][Full Text] [Related]
10. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy strategies for hemophilia: benefits versus risks.
Petrus I; Chuah M; VandenDriessche T
J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
[TBL] [Abstract][Full Text] [Related]
12. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
Hasbrouck NC; High KA
Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
[TBL] [Abstract][Full Text] [Related]
13. Preclinical animal models for hemophilia gene therapy: predictive value and limitations.
Rawle FE; Lillicrap D
Semin Thromb Hemost; 2004 Apr; 30(2):205-13. PubMed ID: 15118932
[TBL] [Abstract][Full Text] [Related]
14. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
Van Damme A; Chuah MK; Collen D; VandenDriessche T
Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical progress in hemophilia gene therapy.
Mátrai J; Chuah MK; VandenDriessche T
Curr Opin Hematol; 2010 Sep; 17(5):387-92. PubMed ID: 20657281
[TBL] [Abstract][Full Text] [Related]
16. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
18. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
Wen J; Vargas AG; Ofosu FA; Hortelano G
J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
[TBL] [Abstract][Full Text] [Related]
19. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy progress and prospects: gene therapy for the hemophilias.
Walsh CE
Gene Ther; 2003 Jun; 10(12):999-1003. PubMed ID: 12776156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
